Product nameAnti-CREBBP antibody - ChIP Grade
See all CREBBP primary antibodies
DescriptionRabbit polyclonal to CREBBP - ChIP Grade
Tested applicationsSuitable for: WB, ChIP, IHC-P, IP, ICC/IF, CHIPseq, Inhibition Assaymore details
Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Non human primates
- HeLa cell lysate. IHC-P: human pancreas FFPE tissue sections
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 99% PBS
Concentration information loading...
PurityImmunogen affinity purified
Primary antibody notesCyclic AMP-responsive enhancer binding protein (CREB) binding protein (CBP) and p300 are closely related transcriptional coactivators that have been shown to directly interact with many different DNA-binding transcription factors including nuclear hormone receptors, CREB (cyclic AMP-responsive enhancer binding protein), c-Fos, c-Jun/v-Jun, c-Myb/v-Myb, TFIIB and MyoD.Both CBP and p300 have been shown to display histone acetyltransferase (HAT) activity, capable of acetylating all four core histone particles in nucleosomes.As a result of HAT activity, it has been suggested CBP and p300 may play a direct role in activating chromatin for transcription.Single point mutations in CBP have been proposed as causative factors in the developmental abnormalities of Rubinstein-Taybi syndrome (RTS).Although both CBP and p300 appear to function similarly, the inability of p300 to rescue CBP malfunction iRTS suggests intrinsic functional differences between CBP and p300.
- Epigenetics and Nuclear Signaling
- Nuclear Signaling Pathways
- Nuclear Receptors
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
ChIP Related Products
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab2832 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 265 kDa (predicted molecular weight: 265 kDa).Can be blocked with Human CREBBP peptide (ab4916).|
|ChIP||Use at an assay dependent concentration. PubMed: 20111703
Recommended to be used at 2-4µg for 1-2x106 cells.
|IHC-P||Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
|IP||Use at an assay dependent concentration. PubMed: 20403362|
|CHIPseq||Use at an assay dependent concentration. PubMed: 22196736|
|Inhibition Assay||Use at an assay dependent concentration.|
FunctionAcetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300.
Involvement in diseaseNote=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with MYST3/MOZ; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with MYST4/MORF. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription.
Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.
Sequence similaritiesContains 1 bromo domain.
Contains 1 KIX domain.
Contains 2 TAZ-type zinc fingers.
Contains 1 ZZ-type zinc finger.
DomainThe KIX domain mediates binding to HIV-1 Tat.
modificationsMethylation of the KIX domain by CARM1 blocks association with CREB. This results in the blockade of CREB signaling, and in activation of apoptotic response.
Phosphorylated upon DNA damage, probably by ATM or ATR.
Sumoylation negatively regulates transcriptional activity via the recruitment of DAAX.
Cellular localizationCytoplasm. Nucleus. Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus.
- Information by UniProt
- CBP antibody
- CBP_HUMAN antibody
- CREB binding protein antibody
Sonicated chromatin prepared from U2OS cells was subjected to the ChIP procedure with ab2832 to CREBBP. Immunoprecipitated chromatin was analysed in the promoter region of c-FOS (active) and in exon 2 of MYO-D (inactive). Values are % of inputs. 2–4 µg of ab2832 and 1-2x106 cells were used in each ChIP experiment.
Sergei Denissov, Prof. Henk Stunnenberg lab, University Nijmengen, NL
Immunofluorescent analysis of MCF-7 cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with DAPI (blue). The nuclear localization of KAT3A/CBP can be observed (green).
IHC image of CREBBP staining in human pancreas formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab2832, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
Immunofluorescent analysis of HeLa cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with DAPI (blue). The nuclear localization of KAT3A/CBP can be observed (green).
Immunohistochemical analysis of FFPE mouse colon tissue, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Heat antigen retrieval performed with 10mM Sodium Citrate (pH 6) for 8-15 minutes. Tissue blocked with 3% H2O2-methanol for 15 minutes at room temperature. Incubation with ab2832 diluted 1/2000 in 3% BSA-PBS overnight at 4°C. Counterstaining with hematoxylin.
Immunofluorescent analysis of NIH-3T3 cells, labeling CREBBP with ab2832 (right) compared with a negative control without ab2832 (left). Cells were formalin fixed, permeabilized with 0.1% Triton X-100 for 5-10 minutes, and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were incubated with anti-KAT3A/CBP diluted 1/100 in 3% BSA/PBS overnight at 4°C. Nuclei were stained with DAPI (blue).
ab2832 using HeLa cell lysate. ab2832 using HeLa cell lysate.
This product has been referenced in:
- Dong H et al. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer. Mol Cancer 18:3 (2019). Read more (PubMed: 30621694) »
- Chen F et al. lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/ß-catenin pathway in oral squamous cell carcinoma. Int J Oncol 54:1183-1194 (2019). Read more (PubMed: 30720068) »